Free Trial
NASDAQ:TLIS

Talis Biomedical (TLIS) Stock Price, News & Analysis

Talis Biomedical logo
$1.60 0.00 (0.00%)
As of 05/9/2025

About Talis Biomedical Stock (NASDAQ:TLIS)

Key Stats

Today's Range
$1.60
$1.60
50-Day Range
$1.50
$1.75
52-Week Range
$1.04
$9.60
Volume
2 shs
Average Volume
3,113 shs
Market Capitalization
$2.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

TLIS Stock News Headlines

Talis Biomedical Corp Ordinary Shares
This robot is coming to 65 million Americans … this year.
The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen Huang recently laid out their vision for the future of robotics.
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
See More Headlines

TLIS Stock Analysis - Frequently Asked Questions

Talis Biomedical's stock was trading at $1.7590 at the start of the year. Since then, TLIS shares have decreased by 9.0% and is now trading at $1.60.
View the best growth stocks for 2025 here
.

Talis Biomedical Co. (NASDAQ:TLIS) announced its earnings results on Tuesday, March, 15th. The company reported ($18.90) earnings per share for the quarter, beating the consensus estimate of ($19.20) by $0.30.

Talis Biomedical shares reverse split before market open on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM).

Company Calendar

Last Earnings
3/15/2022
Today
5/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TLIS
Fax
N/A
Employees
260
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,010,000.00
Pretax Margin
-12,506.37%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Price / Cash Flow
N/A
Book Value
$37.95 per share
Price / Book
0.04

Miscellaneous

Free Float
984,000
Market Cap
$2.92 million
Optionable
No Data
Beta
1.33
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TLIS) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners